Goods & Services

Financial administration of patient reimbursement programs; financial administration of medication reimbursement programs and services. Custom manufacturing of biological tissue, blood, and cells; custom manufacturing of pharmaceutical preparations for immunotherapy. Providing medical information in the fields of oncology, immunology and cell therapy; providing medical information in the fields of oncology, immunology and cell therapy via a web site; providing medical information, consultancy and advisory services in the fields of oncology, immunology and cell therapy; all of the foregoing excluding any services related to optometry, ophthalmology or other ocular care; collection and preservation of biological tissue, blood and cells. Providing patient advocate services in the field of the treatment of diseases and disorders in the fields of cancer treatments, immunotherapy and cell therapy treatments.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for t-cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Abstract

The present disclosure provides allogeneic cells that cause reduced risks of graft-versus-host disease (GVHD) and reduced risk of CD8 and NK cell rejections, for example, when used to treat diseases, such as cancer and/or autoimmune disease, in a patient. The allogeneic cells may be genetically engineered to reduce the expression or activity of CD58. Methods of preparing and using such allogeneic cells are also provided.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/86 - Viral vectors

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for t-cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Abstract

The present disclosure provides allogeneic cells that cause reduced risks of graft-versus-host disease (GVHD) and reduced risk of CDS and NK cell rejections, for example, when used to treat diseases, such as cancer and/or autoimmune disease, in a patient. The allogeneic cells may be genetically engineered to reduce the expression or activity of CD58. Methods of preparing and using such allogeneic cells are also provided.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 49/00 - Preparations for testing in vivo
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 14/725 - T-cell receptors

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Abstract

The present disclosure describes an automated system for physically manipulating sample fluids, capturing images of sample fluids and detecting the presence of particles, characterizing the particles by their features (e.g., size, shape, etc.), and/or identifying particles based on those characteristics.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry

Abstract

The disclosure relates to prognosis and impact of tumor microenvironment on efficacy of cell-based immunotherapy (e.g. T cells, TCR-based therapies, and CAR-based therapies).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Abstract

The present disclosure describes an automated system for physically manipulating sample fluids, capturing images of sample fluids and detecting the presence of particles, characterizing the particles by their features (e.g., size, shape, etc.), and/or identifying particles based on those characteristics.

IPC Classes  ?

• G01N 15/0227 - Investigating particle size or size distribution by optical means using imagingInvestigating particle size or size distribution by optical means using holography
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/02 - Investigating particle size or size distribution

Abstract

The disclosure relates to methods of prognosis and therapy, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, and CAR-based therapies).

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations for use in the treatment of cancer and hematological diseases and disorders; biological preparations for use in the treatment of cancer and hematological diseases and disorders; pharmaceutical and biological preparations for immunotherapy, including cell therapy.

Abstract

The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Abstract

The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 15/86 - Viral vectors

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.

Goods & Services

Pharmaceutical preparations for use in the treatment of cancer and hematological diseases and disorders; biological preparations for use in the treatment of cancer and hematological diseases and disorders; pharmaceutical and biological preparations for immunotherapy, including cell therapy.

Goods & Services

(1) Pharmaceutical preparations for use in the treatment of cancer and hematological diseases and disorders; biological preparations for use in the treatment of cancer and hematological diseases and disorders; pharmaceutical and biological preparations for immunotherapy, including cell therapy.

Abstract

Provided herein are methods for preparing, producing, processing, culturing, isolating, of making cells suitable for immune or cell therapy, and for their use in cell therapy. Further provided are methods for treatment of a cancer patient with such cells.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Compositions and methods for fluorescence activated cell analysis of blood cell populations.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders

Abstract

Provided herein are methods for manufacturing T cells. In certain embodiments, methods for manufacturing T cells which express a cell surface receptor that recognizes a specific antigenic moiety on the surface of a target cell are provided. Also provided herein are populations of engineered T cells produced by the methods described herein and pharmaceutical compositions thereof.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The disclosure relates to methods for treating a malignancy in a subject with a cell therapy, methods of predicting a likelihood of response to the cell therapy product in the subject, and methods of predicting a likelihood of CAR T-cell exhaustion in the cell therapy product.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided herein are methods for expedited manufacturing of engineered lymphocytes which are demonstrated to be associated with a favorable complete response rate and overall survival, and reduced risk of prolonged thrombocytopenia. The expedited manufacturing process can prepare transduced lymphocytes having improved efficacy or reduced adverse effects in treating cancer. An example process includes acquiring lymphocytes from a patient through apheresis, incubating the lymphocytes with a polynucleotide vector to transduce the lymphocytes to produce transduced lymphocytes, culturing the transduced lymphocytes, and infusing the transduced lymphocytes to the patient predicting a likelihood of a complete response, an overall survival rate, and a risk of prolonged thrombocytopenia in a subject receiving an immunotherapy.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Abstract

Provided herein are methods for expedited manufacturing of engineered lymphocytes which are demonstrated to be associated with a favorable complete response rate and overall survival, and reduced risk of prolonged thrombocytopenia. The expedited manufacturing process can prepare transduced lymphocytes having improved efficacy or reduced adverse effects in treating cancer. An example process includes acquiring lymphocytes from a patient through apheresis, incubating the lymphocytes with a polynucleotide vector to transduce the lymphocytes to produce transduced lymphocytes, culturing the transduced lymphocytes, and infusing the transduced lymphocytes to the patient predicting a likelihood of a complete response, an overall survival rate, and a risk of prolonged thrombocytopenia in a subject receiving an immunotherapy.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy. Further provided are methods for treatment of a cancer patient with such cells.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The disclosure relates to methods for treating a malignancy in a subject with a cell therapy, methods of predicting a likelihood of response to the cell therapy product in the subject, and methods of predicting a likelihood of CAR T-cell exhaustion in the cell therapy product.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The disclosure relates to chimeric antigen receptor (CAR) specific to CD 19, vectors encoding the same, and recombinant T cells comprising the CD 19 CAR. The disclosure also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD 19 binding domain.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD 19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL-18), compositions comprising the T cells, and methods of generating and/or using the T cells to treat diseases associated with the expression of CD 19.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/54 - Interleukins [IL]
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through cytokine signaling or cytokine receptor signaling.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/52 - CytokinesLymphokinesInterferons
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Embodiments of the disclosure relate to shipping cases, dewars, and systems for transporting a frozen material. More specifically, the embodiments described herein include and/or enable dewar lid protective systems, data logging enablement, controlled coolant escape, efficient stacking options during transport, spill protection to ensure safe and effective transport of frozen samples and materials among other things. An exemplary use for the systems described herein includes reliable shipping for frozen materials at specified environmental conditions which can be tracked and verified.

IPC Classes  ?

• B65D 85/30 - Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
• B65D 45/02 - Clamping or other pressure-applying devices for securing or retaining closure members for applying axial pressure to engage closure with sealing surface
• B65D 81/127 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents specially adapted to protect contents from mechanical damage maintaining contents at spaced relation from package walls, or from other contents using rigid or semi-rigid sheets of shock-absorbing material
• F17C 13/00 - Details of vessels or of the filling or discharging of vessels

Abstract

Embodiments of the disclosure relate to shipping cases, dewars, and systems for transporting a frozen material. More specifically, the embodiments described herein include and/or enable dewar lid protective systems, data logging enablement, controlled coolant escape, efficient stacking options during transport, spill protection to ensure safe and effective transport of frozen samples and materials among other things. An exemplary use for the systems described herein includes reliable shipping for frozen materials at specified environmental conditions which can be tracked and verified.

IPC Classes  ?

• F25D 3/10 - Devices using other cold materialsDevices using cold-storage bodies using liquefied gases, e.g. liquid air
• F17C 13/08 - Mounting arrangements for vessels

Abstract

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through cytokine signaling or cytokine receptor signaling.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/54 - Interleukins [IL]
• A61K 38/20 - Interleukins
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

A method for bioprocessing includes the steps of providing a bioprocessing system having a first bioreactor vessel and a second bioreactor vessel, activating a population of cells in the first bioreactor vessel, genetically modifying the population of cells to produce a population of genetically modified cells, and expanding the population of genetically modified cells within the first bioreactor vessel and the second bioreactor vessel.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells